Captrust Financial Advisors Sells 5,801 Shares of OmniAb, Inc. (NASDAQ:OABI)

Captrust Financial Advisors lessened its holdings in OmniAb, Inc. (NASDAQ:OABI) by 25.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,599 shares of the company’s stock after selling 5,801 shares during the quarter. Captrust Financial Advisors’ holdings in OmniAb were worth $70,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Atria Investments Inc bought a new stake in shares of OmniAb in the third quarter valued at about $148,000. Isthmus Partners LLC lifted its position in OmniAb by 37.2% during the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after purchasing an additional 143,387 shares during the period. Rice Hall James & Associates LLC lifted its position in OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares during the period. The Manufacturers Life Insurance Company bought a new stake in OmniAb during the second quarter worth about $147,000. Finally, Sei Investments Co. lifted its position in OmniAb by 11.0% during the second quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after purchasing an additional 2,888 shares during the period. Institutional investors own 72.08% of the company’s stock.

OmniAb Price Performance

OmniAb stock opened at $3.79 on Tuesday. The business has a 50 day moving average of $4.03 and a 200-day moving average of $4.19. OmniAb, Inc. has a 1 year low of $3.56 and a 1 year high of $6.72. The company has a market capitalization of $535.21 million, a P/E ratio of -6.11 and a beta of -0.14.

Analyst Ratings Changes

A number of research firms have recently commented on OABI. Benchmark reissued a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.